Business
MedMira to Participate in Military Health System Research Symposium
HALIFAX, Aug. 13, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid di...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n\n\n\nHALIFAX, Aug. 13, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a\n developer of rapid diagnostic technology and solutions, announced today\n that it is participating in the Military Health System Research\n Symposium (MHSRS) taking place August 13-16, 2012 in Fort Lauderdale,\n FL. During the symposium, MedMira will discuss and demonstrate its\n unique multiplex rapid diagnostics which are critical tools in the\n treatment and care of individuals wounded in combat.\n\n\nMHSRS is the premier scientific meeting to address the unique medical\n needs of the warfighter. The symposium is a collaborative environment\n for military medical care providers with deployment experience,\n Department of Defense (DoD) scientists, academia, and industry to\n facilitate discussions and address the advancement of research and\n health care development in areas of Combat Casualty Care, Military\n Operational Medicine, Clinical and Rehabilitative Medicine, and\n Military Infectious Disease Research Programs.\n\n\n\"This event provides us with an ideal opportunity to showcase our rapid\n diagnostics and technology platform and allows us to continue building\n key relationships with military healthcare personnel within the US Army\n and other military organizations around the world,\" said Hermes Chan,\n CEO, MedMira Inc.  \"MHSRS attendees will be keen to see and learn more\n about our Multiplo Rapid HBV/HIV/HCV Antibody Test, for which we were\n recently awarded a US Army contract to advance, fully commercialize,\n and obtain US Food and Drug Administration approval.\"\n\n\nIn July 2012, MedMira was awarded a U.S. Army Medical Research\n Acquisition Activity (USAMRAA) contract valued at USD$4,266,144 to\n advance and fully commercialize its multiple rapid test that\n simultaneously detects three of the most serious infectious diseases,\n namely HIV-1/2, Hepatitis B, and C antibodies within three minutes\n using just a small drop of blood.\n\n\nAbout MedMira\n\n\nMedMira is a leading developer and manufacturer of flow-through rapid\n diagnostics and technologies. The Company's tests provide hospitals,\n labs, clinics and individuals with reliable, rapid diagnosis for\n diseases such as HIV and hepatitis C in just three minutes. The\n company's tests are sold under the Reveal®, Multiplo™ and Miriad brands\n in g...